Melanoma Clinical Trial
Official title:
A Comparison of Interventions to Teach Melanoma Patients Skin Self-examination
The almost 724,000 Americans survivors of melanoma are estimated to have 4 first degree relatives per case; thus, 2.8 million Americans are at increased risk of developing melanoma in comparison to the general public. Skin self-examination (SSE) with the assistance of a partner by these individuals could improve survival. If effective, the workbook tested in this proposal could be distributed to people at risk of developing melanoma by large scale means in physicians office.
Population based registries document that survival from melanoma, a growing public health
problem with approximately 70,000 new melanoma cases and an estimated 8,600 deaths in 2010,
is dependent on the thickness of the melanoma. By facilitating seeking medical care, skin
self-examinations (SSEs) by individuals with a prior history of melanoma, who are at risk to
develop subsequent melanomas, may lead to the early detection and treatment of melanoma when
it is usually more effective. Thus, further research that enhances early detection is
warranted and our application directly tests novel methods of training high-risk melanoma
patients and their partners on how to conduct SSEs to promote early detection. Our proposed
research builds upon the strengths of the R21 that: a) established that in-person training
to conduct SSE with a partner significantly enhanced SSE performance 4 months after the
intervention, and b) developed and pilot tested a manualized take-home workbook training
approach (WORKBOOK). Our pilot work on the WORKBOOK with partners suggests that
patient-partner dyads (n = 21) perceived it to be readable, useful, and in the short term 4
month follow-up, empirically equivalent in promoting SSE knowledge, skills, and behaviors
compared with patient-partner dyads in the in-person partner training condition (n = 19).
Our proposed research builds on our NCI funded studies by conducting a formal examination
with 430 pairs (860 subjects) randomized to either the in-person or workbook training vs. an
assessment only control group that receives standard of care over a 2 year longitudinal
study with 4 month interval evaluations. An additional group of 70 pairs (140 subjects) has
been added to test a tablet computer-based program.
Our proposed research directly tests novel methods of training Stage I and IIB melanoma
patients, who have a 5 year survival of 80-90%, and their partners, on how to conduct SSEs.
We will compare the efficacy of the in-person training vs. workbook for patients and
partners vs. controls on SSE knowledge/skill acquisition and retention, and SSE performance
and accuracy on a short (4 and 8 months post baseline) and long term basis (12, 16, 20, and
24 months post baseline) and examine whether partner-patient relationship-qualities moderate
the relationship between the training approaches and SSEs knowledge/skill acquisition and
retention, and SSE performance and accuracy. The tablet computer-based program will also be
tested for efficacy and compared with the previous groups.
Establishing health promotion partnerships is important to those at risk to develop melanoma
because SSE is difficult to successfully perform as an individual. It is expected that the
workbook will promote SSE at least as well as and perhaps better than in-person training and
become an easily disseminated SSE training approach that is not dependent on the time and
teaching skills of the non-MD clinical office staff.
;
Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Screening
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT05094804 -
A Study of OR2805, a Monoclonal Antibody Targeting CD163, Alone and in Combination With Anticancer Agents
|
Phase 1/Phase 2 | |
| Completed |
NCT03979872 -
Risk Information and Skin-cancer Education for Undergraduate Prevention
|
N/A | |
| Recruiting |
NCT04986748 -
Using QPOP to Predict Treatment for Sarcomas and Melanomas
|
||
| Enrolling by invitation |
NCT00068003 -
Harvesting Cells for Experimental Cancer Treatments
|
||
| Recruiting |
NCT05707286 -
Pilot Study to Determine Pro-Inflammatory Cytokine Kinetics During Immune Checkpoint Inhibitor Therapy
|
||
| Active, not recruiting |
NCT05470283 -
Phase I, Open-Label, Study of Tumor Infiltrating Lymphocytes Engineered With Membrane Bound IL15 Plus Acetazolamide in Adult Patients With Metastatic Melanoma
|
Phase 1 | |
| Recruiting |
NCT05077137 -
A Feasibility Study Utilizing Immune Recall to Increase Response to Checkpoint Therapy
|
Phase 1 | |
| Active, not recruiting |
NCT02721459 -
XL888 + Vemurafenib + Cobimetinib for Unresectable BRAF Mutated Stage III/IV Melanoma
|
Phase 1 | |
| Completed |
NCT00341939 -
Retrospective Analysis of a Drug-Metabolizing Genotype in Cancer Patients and Correlation With Pharmacokinetic and Pharmacodynamics Data
|
||
| Recruiting |
NCT05839912 -
Excision of Lymph Node Trial (EXCILYNT) (Mel69)
|
N/A | |
| Recruiting |
NCT04971499 -
A Study of Dapansutrile Plus Pembrolizumab in Patients With PD-1 Refractory Advanced Melanoma
|
Phase 1/Phase 2 | |
| Recruiting |
NCT05263453 -
HL-085+Vemurafenib to Treat Advanced Melanoma Patients With BRAF V600E/K Mutation
|
Phase 2 | |
| Active, not recruiting |
NCT05060432 -
Study of EOS-448 With Standard of Care and/or Investigational Therapies in Participants With Advanced Solid Tumors
|
Phase 1/Phase 2 | |
| Not yet recruiting |
NCT06413680 -
A First-In Human (FIH) Trial to Find Out if REGN10597 is Safe and How Well it Works for Adult Participants With Advanced Solid Organ Malignancies
|
Phase 1/Phase 2 | |
| Terminated |
NCT03399448 -
NY-ESO-1-redirected CRISPR (TCRendo and PD1) Edited T Cells (NYCE T Cells)
|
Phase 1 | |
| Completed |
NCT03348891 -
TNF in Melanoma Patients Treated With Immunotherapy
|
N/A | |
| Completed |
NCT03171064 -
Exercise as a Supportive Measure for Patients Undergoing Checkpoint-inhibitor Treatment
|
Phase 2 | |
| Not yet recruiting |
NCT05539118 -
Interferon-α1b Combined With Toripalimab and Anlotinib Hydrochloride in Advanced Unresectable Melanoma
|
Phase 1/Phase 2 | |
| Recruiting |
NCT05171374 -
pRospective Evaluation of Clinical Outcomes in Patients With metAsTatIс melanOma Treated With dabrafeNib and trAmetinib in reaL practicE
|
||
| Withdrawn |
NCT02854488 -
Yervoy Pregnancy Surveillance Study
|